Karlsson, Johan; Tzeng, Stephany Y.; Hemmati, Shayan; Luly, Kathryn M.; Choi, Olivia; Rui, Yuan; Wilson, David R.; Kozielski, Kristen L.; Quinones-Hinojosa, Alfredo; Green, Jordan J. published an article in 2021. The article was titled 《Photocrosslinked Bioreducible Polymeric Nanoparticles for Enhanced Systemic siRNA Delivery as Cancer Therapy》, and you may find the article in Advanced Functional Materials.SDS of cas: 13325-10-5 The information in the text is summarized as follows:
Clin. translation of polymer-based nanocarriers for systemic delivery of RNA has been limited due to poor colloidal stability in the blood stream and intracellular delivery of the RNA to the cytosol. To address these limitations, this study reports a new strategy incorporating photocrosslinking of bioreducible nanoparticles for improved stability extracellularly and rapid release of RNA intracellularly. In this design, the polymeric nanocarriers contain ester bonds for hydrolytic degradation and disulfide bonds for environmentally triggered small interfering RNA (siRNA) release in the cytosol. These photocrosslinked bioreducible nanoparticles (XbNPs) have a shielded surface charge, reduced adsorption of serum proteins, and enable superior siRNA-mediated knockdown in both glioma and melanoma cells in high-serum conditions compared to non-crosslinked formulations. Mechanistically, XbNPs promote cellular uptake and the presence of secondary and tertiary amines enables efficient endosomal escape. Following systemic administration, XbNPs facilitate targeting of cancer cells and tissue-mediated siRNA delivery beyond the liver, unlike conventional nanoparticle-based delivery. These attributes of XbNPs facilitate robust siRNA-mediated knockdown in vivo in melanoma tumors colonized in the lungs following systemic administration. Thus, biodegradable polymeric nanoparticles, via photocrosslinking, demonstrate extended colloidal stability and efficient delivery of RNA therapeutics under physiol. conditions, and thereby potentially advance systemic delivery technologies for nucleic acid-based therapeutics.4-Aminobutan-1-ol(cas: 13325-10-5SDS of cas: 13325-10-5) was used in this study.
4-Aminobutan-1-ol(cas: 13325-10-5) is used in the synthesis of NSAIDs with anti-inflammatory properties. Also used in the synthesis of polyamine transport ligands with specificity against human cancers allowing easy access to specific cancer cells.SDS of cas: 13325-10-5
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts